Generalized Anxiety Disorder Clinical Trial
Official title:
Cognitive-behavioral Therapy (CBT) for Generalized Anxiety Disorder: Preliminary Data of Various Contrasting CBT Approaches in a Randomized Clinical Trial
Cognitive-behavior therapy (CBT) is considered the "golden standard" psychotherapy for generalized anxiety disorder (GAD). However, it entails different approaches and blanket statements remain hard to formulate. We conducted a randomized controlled trial to compare the most studied CBT protocol for GAD - Borkovec's treatment package - with two other forms : Rational Emotive Behavior Therapy and Acceptance and Commitment Therapy.
The goal of our present study is to compare the most established and studied CBT protocol for
GAD, namely Borkovec's treatment package (BTP) with two other forms of CBT: Rational Emotive
Behavior Therapy (REBT; Ellis, 1977) and Acceptance and Commitment Therapy (ACT; Hayes et
al., 2012). These two forms of therapy were chosen for both conceptual and practical reasons.
At a conceptual level, we wanted to compare forms of CBT with distinct approaches to
dysfunctional thoughts. A fundamental postulate of the cognitive model of psychopathology is
that the modification of dysfunctional thoughts (i.e., cognitive change) is central to
treating psychological disorders, as "all therapies work by altering dysfunctional
cognitions, either directly or indirectly". Both classical Beck's cognitive therapy (CT;
Beck, 1976), which is an integrated part in Borkovec's GAD treatment package (CT/BTP), and
REBT focus on changing dysfunctional thoughts, but they differ fundamentally in their
approach to achieving this change. More specifically, Beck's CT focuses primarily on
modifying mental representations of relevant circumstances in the forms of dysfunctional
descriptions and inferences (i.e., "cold" cognitions: "I will fail."). REBT on the other hand
focuses mainly on "hot" cognitions in the form of evaluations/appraisals (i.e., rational and
irrational beliefs), which refer to the ways in which "cold" cognitions/ representations are
processed in terms of their relevance for personal well-being (i.e., "I must not fail and it
is awful if I fail."). In contrast to both CT and REBT, ACT does not directly attempt to
modify the content of the thoughts at all, but aims to change the individual's relationship
to dysfunctional beliefs (i.e., the significance of having these beliefs), a process through
which cognitions are thought to become "neutralized" (i.e., defused) and the anxiety/distress
related to them is reduced or accepted.
At a practical level, we wanted to investigate how different forms of CBT (i.e., REBT and
ACT/ABBT) would measure up to the established package based on Borkovec's treatment protocol
(CT/BTP).
According to REBT, core irrational beliefs (e.g., "I must not fail and it is awful if I
fail."), in interaction to various activating events (e.g., a test situation), generate
automatic thoughts in the form of descriptions/inferences (e.g., "I will fail here.") that
are then further processed by automatic thoughts in the form of specific irrational beliefs
derived from the core irrational beliefs (e.g., "I must not fail here and it is awful if I
fail here.") that than further generate anxiety symptoms. In its general form, REBT is
focused on changing both core beliefs and automatic thoughts, but in its specific form, used
here, REBT is focused on changing the core irrational beliefs seen as the fundamental
etiopathogenetic mechanisms of GAD.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT01958788 -
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01681329 -
Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT01337713 -
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
|
N/A | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00368745 -
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
|
Phase 3 |